Company ProfilePremium

Cumulex N.V.

Company Profile Analysis

Ticker: CLEX.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cumulex N.V. - Company showcase

Year Founded & Workforce

1956

Cumulex N.V. logo

Cumulex N.V. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cumulex N.V. Overview

Cumulex NV is a 70-year-old Belgian listed company that has no operating activities. It describes itself as a stock-exchange vehicle without activities. Its value proposition is the listing itself: a regulated-market quotation on Euronext Brussels that a private company could use to go public through a reverse listing, or into which a controlling shareholder could contribute businesses.

The company descends from Sucraf, which co-owned a sugar plantation and refinery in the Democratic Republic of Congo (Sucrerie de Kiliba). That stake is now carried at EUR 1. Since about 2014 the shell has been controlled and financed by the Dutch investment company Value8, which holds 75.75% of the votes and an interest-free claim of EUR 2.52 million on Cumulex.

The only acquisition attempt since the rename was a planned purchase of Value8's 65% stake in Dutch demolition firm AA Circular. Shareholders approved it in January 2023, but it was never completed. The equity story is therefore entirely about deal optionality, set against negative equity of EUR −2.54 million.


Company's own description (latest annual report, FY2025, paraphrased from Dutch). Cumulex, formerly Sucraf, is a Belgian NV. The board's strategy is to bring new activities into the company. It will look for suitable opportunities in consultation with counterparties. A reverse listing, in which a private company obtains a stock-exchange listing through Cumulex, is explicitly one of the routes. Candidates are screened on three criteria:

  • an attractive value proposition for security holders;

  • profitability and earnings per share;

  • long-term value-growth prospects.

The primary objective remains medium- to long-term value creation. The board reserves the right to depart from these criteria if better opportunities arise. It also notes that, although not currently expected, restarting operations or liquidating the company could prove more attractive than a reverse listing (AR FY2025, board report).

The homepage frames the company similarly. It calls Cumulex a listed company without activities, invites investment proposals, and lists six screening attributes (Cumulex website, accessed Oct 2026):

  • value proposition;

  • profitability;

  • EPS contribution;

  • long-term value growth;

  • good track record;

  • strong management.

Independent characterisation.

Business model: a listed shell ("beurshuls"). It generates no revenue and incurs about EUR 70–90k a year in listing-maintenance costs: the statutory auditor, FSMA, Euronext, Euroclear and mandatory legal notices (AR FY2025). Value8 funds these costs through non-interest-bearing advances.

Revenue model mix: product 0%, service 0%, subscription 0%, licensing 0%. Revenue has been nil every year FY2021–FY2025 (statutory income statements).

Value chain position: none in an industrial sense. In capital-markets terms, Cumulex sits at the "listing supply" end of the market. It offers listing status, a shareholder register, and about EUR 6.44 million of Belgian tax-loss carryforwards to a would-be acquirer. Use of those losses is uncertain after a change of control (AR FY2025, note 6.13).

Customer types: none in the conventional sense. The target "customers" are (a) private companies seeking a quotation, and (b) Value8 portfolio companies that could be injected.

End-markets served: none at present. Data vendors classify the company variously as "Non-operating Establishments" (StockAnalysis), "Activities of holding companies and financing conduits" (FinancialFilings), and "consumer goods", a legacy sugar classification (Beursgenoten/ShareCompany). These classifications conflict, which reflects the absence of any operating business.

Legacy asset. Cumulex still records a 33% interest (32,997 capital shares) in Sucrerie de Kiliba-Sucki Sarl, DRC. Historical cost is EUR 9,317,680.58, fully impaired to EUR 1. A related receivable of nominal EUR 1,340,664.52 is also written down to EUR 1. The board states there are no developments regarding Kiliba and no expectation of any proceeds (AR FY2025).

Strategy

Stated strategy themes (latest filings, paraphrased).

  1. Bring in or acquire operating businesses to create long-term value (H1 2025 release; AR FY2025).

  2. Pursue investments, stakes in companies and/or a reverse listing, so that sustainable value growth becomes possible and a base exists that is proportionate to listing costs (H1 2026 release, 31 Jul 2026).

  3. Screen targets on an attractive value proposition, a positive effect on profitability and EPS, and healthy long-term growth (FY2024 and FY2025 releases).

  4. Keep alternative outcomes open: restarting operations or liquidation, if more value-accretive (AR FY2025).

  5. Possibly strengthen the balance sheet by converting Value8's claim into (preferred) securities on market-conform terms, potentially including the EUR 1.2m conditionally waived debt. The board states these proposals are not yet concrete (AR FY2025).

Initiatives in the last 24 months

Medium-term financial targets / guidance: none published.

Investor day: none held.

Products & Services

Cumulex has no products, brands, platforms or service offerings. Its de facto "offerings" are listed below for completeness. None are priced or sold.

Legacy (historical) business. Sucraf's historical business was the co-ownership of a sugar plantation and refinery at Kiliba (DRC). No specifications, volumes or product data are publicly disclosed in the documents reviewed.

Product Portfolio

"Offering"DescriptionTarget counterpartySincePricing modelSource

Reverse-listing vehicle

A Euronext Brussels regulated-market quotation available to a private company that merges into, or is contributed to, Cumulex

Private companies seeking a listing; Value8 portfolio companies

Strategy stated since at least 2021

Not publicly disclosed (would be negotiated per deal)

cumulex.be; AR FY2025

Investment platform

Vehicle for "investments, taking stakes in companies and/or a reverse listing"

Same as above

Restated 31 Jul 2026

—

Press release 31 Jul 2026

Tax-loss carryforwards (embedded attribute)

EUR 6,444,660 of Belgian carry-forward losses, usable without time limit in principle. Survival after a change of control is uncertain unless the change meets "legitimate financial or economic needs" under the Belgian Income Tax Code (WIB 1992)

Acquirer of control

Accumulated mostly pre-2011

—

AR FY2025 note 6.13

“—” = not publicly disclosed.

Financial Narrative

Basis of preparation. The accounts are Belgian GAAP statutory accounts under the Royal Decree of 29 April 2019, not IFRS. They are unconsolidated. All figures are in EUR (not thousands), taken from audited balance sheets and income statements:

  • FY2021 and FY2022: AR FY2022.

  • FY2023: AR FY2023.

  • FY2024 and FY2025: AR FY2025.

Income statement

Notes:

  • FY2021 YoY is shown as 0 because the FY2020 comparable is EUR −29k per the FY2020 press release, a +124% jump not shown in the table.

  • Gross, operating, EBITDA and net margins are undefined (division by zero revenue). The revenue CAGR is undefined.

  • The operating cost CAGR for FY2021–FY2025 is +3.6% a year (analyst calc.).

  • Cumulative net losses for FY2021–FY2025 total EUR 377,338.

Press-release error: the FY2023 press release compares the FY2023 loss of EUR −76k with "2021: −91 thousand". The −91k figure is in fact FY2022. This is a labelling error in the company's own release.

Commentary. The cost base consists entirely of listing-compliance costs. The FY2022 spike (+40.8%) is explicitly attributed in AR FY2022 to the preparation of the AA Circular acquisition: three shareholder meetings, a special board report and advisory work. FY2023 also carried some deal-preparation cost per AR FY2023. Costs then normalised at about EUR 70–75k.

The statutory auditor's fee alone is a large share of the cost base:

Sources: AR notes 6.16; ratios are analyst calculations. Directors and major shareholders received no remuneration in FY2022–FY2025 (AR FY2025).

Half-year results history

Sources: half-year press releases (4 Sep 2020, 13 Sep 2021, 5 Aug 2022, 29 Sep 2023, 26 Sep 2024, 30 Sep 2025, 31 Jul 2026). H1 2026 EPS was −7.7 euro cents (H1 2025: −7.5 cents). H1 2023 is cited as −45k by the company; ABM FN reported the same. The H1 2022 release gives −34k, while the H1 2023 release cites the H1 2022 comparable as −35k (rounding discrepancy).

Balance sheet

The FY2021 increase in the Value8 claim is shown as 0 because it is not disclosed in the reviewed documents.

Key off-balance-sheet items (AR FY2025 notes 6.14 and 6.15):

  1. Conditional debt waiver of EUR 1,205,262. Value8, as assignee of the Sopex claim, has waived this amount subject to a "retour à meilleur fortune" clause, so it would revive if Cumulex's finances recover.

  2. Letter of support. Value8 has given an irrevocable and unconditional letter of support guaranteeing continuity until at least the AGM of 14 June 2027.

  3. Authorised capital. The articles authorise a capital increase of up to EUR 1,835,000.

  4. No interest. The Value8 claim bears no interest.

Commentary. The balance sheet is a pure liability structure. Assets are effectively nil (EUR 104 at FY2025). Equity has deteriorated every year by roughly the annual loss, because Value8 funds the cash burn with interest-free advances that add one-for-one to liabilities. The equity deficit (−EUR 2.54m) is larger than issued capital (EUR 1.84m).

Cash flow (no cash-flow statement published; analyst derivation)

Cumulex files abbreviated Belgian statutory accounts and does not present a cash-flow statement. The table below derives operating cash flow as: change in cash minus the increase in the related-party claim. This is an approximation; FY2021 is not derivable from the reviewed documents.

AR FY2025 confirms that no own shares were acquired in the year.

Commentary. Cumulex has no self-generated cash flow. It typically ends each year with near-zero cash (EUR 102–3,203). Value8 drip-feeds about EUR 72–90k a year, which is effectively equity support booked as debt.

Ratios

Computable ratios (analyst calculations from statutory accounts)

Ratios that are not meaningful

Trend summary and inflections.

2021–2022 inflection: The AA Circular project lifted costs to a peak of EUR 91k.

2023–2024: Costs normalised once the deal stalled.

2025: Costs rose 6%, consistent with a higher audit fee (EUR 32.8k).

H1 2026: Steady at −EUR 42k.

The structural driver is unchanged: a fixed listing cost with no revenue. Each year adds about EUR 75k to Value8's claim and the equity deficit.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipStakeCarrying value (FY2025)Status

Value8 NV (Bussum, NL)

Parent / controlling shareholder

75.75% of votes in Cumulex

—

Active; funds Cumulex

Cumulex NV (Diegem, BE)

Listed company

——

Dormant shell

Sucrerie de Kiliba-Sucki Sarl (DRC)

Associate (legacy)

33% (32,997 shares)

EUR 1 (stake) + EUR 1 (receivable)

No developments; no proceeds expected

Revenue by Segment (EUR) and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Segment revenue (EUR)

000

Segment operating result (EUR)

-75,906-70,558-74,797

Segment pre-tax result (EUR)

-75,906-70,558-74,797

% contribution to total revenue

000

Operating cost YoY growth (%)

-16.8-7.06.0

Income Statement (EUR) and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (EUR)

00000

Gross profit (EUR)

00000

Operating costs — services and miscellaneous goods (EUR)

64,82591,25275,90670,55874,797

Operating income / EBIT (EUR)

-64,825-91,252-75,906-70,558-74,797

EBITDA (EUR, no D&A booked)

-64,825-91,252-75,906-70,558-74,797

Financial result (EUR)

00000

Pre-tax income (EUR)

-64,825-91,252-75,906-70,558-74,797

Income tax (EUR)

00000

Net income (EUR)

-64,825-91,252-75,906-70,558-74,797

EPS per voting instrument, 550,000 basis, as reported by company (EUR)

-0.12-0.17-0.14-0.13-0.14

EPS per listed share, 440,000 basis, analyst calc. (EUR)

-0.15-0.21-0.17-0.16-0.17

Diluted EPS (EUR, no dilutive instruments outstanding)

-0.12-0.17-0.14-0.13-0.14

Dividends per share (EUR)

00000

Operating cost YoY change (%)

040.8-16.8-7.06.0

Auditor Fee by Fiscal Year

Fiscal yearAuditor fee (EUR)Share of total costs

FY2022

27,500 audit + 7,508 other assurance

38%

FY2023

28,135 audit + 2,905 other

41%

FY2025

32,840 audit

44%

Key Financials

MetricH1 2020H1 2021H1 2022H1 2023H1 2024H1 2025H1 2026

Net / operating result (EUR K)

-14-38-34-45-32-41-42

Balance Sheet (EUR)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (EUR)

8,6061482113,205104

Financial fixed assets — Kiliba stake + receivable (EUR)

22222

Cash and equivalents (EUR)

8,6041462093,203102

Trade payables (EUR)

16,24035,53329,02630,07824,274

Other short-term liabilities (EUR)

2,220,2292,283,7302,366,2062,438,7062,516,206

of which owed to Value8, non-interest-bearing (EUR)

2,188,7062,278,7062,366,2062,438,7062,516,206

Short-term debt — total liabilities due within 1 year (EUR)

2,236,4692,319,2632,395,2322,468,7842,540,480

Long-term debt (EUR)

00000

Net debt — Value8 claim minus cash, analyst calc. (EUR)

2,180,1022,278,5602,365,9972,435,5032,516,104

Issued capital (EUR)

1,835,0001,835,0001,835,0001,835,0001,835,000

Legal reserve (EUR)

6,0306,0306,0306,0306,030

Accumulated losses carried forward (EUR)

-4,068,893-4,160,145-4,236,051-4,306,609-4,381,406

Total equity (EUR)

-2,227,863-2,319,115-2,395,021-2,465,579-2,540,376

Goodwill and intangibles (EUR)

00000

Working capital — current assets minus current liabilities (EUR)

-2,227,865-2,319,117-2,395,023-2,465,581-2,540,378

Annual increase in Value8 claim (EUR)

090,00087,50072,50077,500

Cash Flow (EUR)

MetricFY2022FY2023FY2024FY2025

Change in cash (EUR)

-8,458632,994-3,101

Funding from Value8 — increase in claim (EUR)

90,00087,50072,50077,500

Implied operating cash flow (EUR)

-98,458-87,437-69,506-80,601

Capex (EUR)

0000

Free cash flow — implied (EUR)

-98,458-87,437-69,506-80,601

Dividends paid (EUR)

0000

Share buybacks (EUR)

0000

Financial Ratios (x) and Balance Sheet (EUR)

MetricFY2021FY2022FY2023FY2024FY2025

Current ratio (x)

0.00380.00010.00010.00130.0000

Total liabilities / equity (x)

-1.00-1.00-1.00-1.00-1.00

Value8 claim per voting instrument, 550,000 basis (EUR)

3.984.144.304.434.57

Book equity per voting instrument, 550,000 basis (EUR)

-4.05-4.22-4.35-4.48-4.62

Asset turnover (x)

00000

Financial Analysis

RatioStatusReason

ROE

Not meaningful

Negative net income divided by negative equity yields a spurious positive figure

ROA

Not meaningful

Total assets of EUR 104–8,606 produce four- to five-figure negative percentages

ROIC

Not meaningful

Invested capital is negative

Net debt / EBITDA

Not meaningful

EBITDA is negative (FY2025: net debt EUR 2.52m vs EBITDA −EUR 0.075m)

Interest coverage

Undefined

No interest expense; the Value8 claim is interest-free

Debt / equity

Not meaningful

Equity is negative

Cash conversion cycle

Not applicable

No revenue, inventory or receivables

Gross / operating / EBITDA / net margins

Undefined

Zero revenue

Geographic Revenue

MetricFY2021FY2022FY2023FY2024FY2025

Revenue — Belgium (EUR)

00000

Revenue — Rest of Europe (EUR)

00000

Revenue — Africa / DRC (EUR)

00000

Revenue — Total (EUR)

00000

Valuation Snapshot

MetricValueSource

Last price

EUR 0.66 (last trade 30 Sep 2026)

Beursgenoten

52-week range

EUR 0.66 – 0.755

StockAnalysis (as of Jul 2026)

Market cap change (as shown)

−9.0% (period basis not specified by vendor)

StockAnalysis

1-year performance

Not reliably determinable. The price sits at the 52-week low of EUR 0.66, against a high of EUR 0.755

StockAnalysis

3-year performance

Not publicly verifiable from reviewed sources

—

5-year performance

Not publicly verifiable. An IEX.nl reader comment on 20 Dec 2021 cited a price of about EUR 2.94 on that day's active trading

IEX.nl comment

Beta

0.75 (vendor figure; statistically unreliable given illiquidity)

StockAnalysis

Liquidity

Prior-session volume of 4 shares; frequent no-trade days

Beursgenoten

Valuation Snapshot — Market cap

MetricValue

Market cap (440,000 shares × 0.66)

290,400

Plus: Value8 claim

2,516,206

Less: cash

102

Enterprise value

2,806,504

P/E

Not meaningful (negative EPS)

EV/EBITDA

Not meaningful (negative EBITDA)

EV/Sales

Not meaningful (zero sales)

P/B

Not meaningful (negative book value)

Market cap / annual cash burn

≈3.9x (290,400 / 74,797)

Capital Markets

MetricFY2021FY2022FY2023FY2024FY2025

Dividend per share (EUR)

00000

Buybacks (EUR)

00000

Capital Markets — Moody's / S&P / Fitch

ItemDetail

Moody's / S&P / Fitch

Not rated

Debt instruments

No bonds or bank debt. Total financial debt is the EUR 2,516,206 Value8 current-account claim (interest-free, short-term)

Debt maturity profile

100% classified as due within one year, but supported by the letter of support to Jun 2027

Convertible bond (AA Circular)

Approved but never issued; no outstanding conversion rights (AR FY2025 note 6.7.1 shows nil convertibles)

Analyst Conclusions

Management guidance: none quantitative. Qualitatively, management continues to pursue investments, stakes and/or a reverse listing (H1 2026 release).

Consensus: no analyst coverage, so there is no consensus.

Run-rate expectation (analyst). Absent a transaction, FY2026 should show a loss of about EUR 75–85k (H1 2026: EUR 42k). Equity would deteriorate to about −EUR 2.62m, and the Value8 claim would rise to about EUR 2.6m.

Bull case (data-grounded)

  1. Cheap option on a deal. For EUR 290k of market cap, investors hold an option on a reverse listing. The one deal structured so far implied a pro forma diluted EPS of about EUR 0.20 (press release 1 Feb 2022), roughly 30% of today's share price.

  2. A motivated sponsor. Value8 has funded the shell for over a decade, renewed its support to 2027, and has a documented record of moving assets between its listed vehicles.

  3. Balance-sheet repair would unlock value. Converting the EUR 2.52m claim, plus potentially the EUR 1.21m conditional waiver, would restore positive equity. Combined with EUR 6.44m of tax losses, this could make the shell attractive to a profitable target.

Bear case (data-grounded)

  1. Structural cash drain. EUR 377k of cumulative losses over FY2021–FY2025 are added one-for-one to a senior related-party claim that ranks ahead of shareholders.

  2. Minority value is likely to be diluted heavily. Any recapitalisation or injection is priced against negative equity. The AA Circular terms would have reduced minorities from about 24% to about 9%.

  3. Execution and governance record. One deal in five years, unfinished three years after approval. Auditor-flagged statutory breaches. Illiquid trading that prevents an orderly exit.

Catalysts and monitorables (next 12 months)

Concluding analyst verdict. Cumulex NV is best understood as a listed legal shell held in reserve by Value8, not as an operating company. Its financial statements are almost purely a ledger of compliance costs. Annual costs of about EUR 75k are funded by interest-free advances from its controlling shareholder. Equity stands at −EUR 2.54 million, total assets are EUR 104, and there are no employees, no revenue and no analyst coverage.

The only substantive attempt to change this was the 2022–2023 plan to acquire Value8's 65% stake in Dutch demolition contractor AA Circular. Shareholders approved it, but the target's bank never consented. The plan has been effectively dormant since early 2024.

The June 2026 board expansion is a genuine, if overdue, response to auditor-flagged breaches of Belgian company law. It does not change the economics. With Frank Lagerveld's death weeks after his appointment, the board is again below its intended size.

For a minority investor, the position is a deep-out-of-the-money option. Upside depends on three things happening together: Value8 sourcing an attractive asset, converting its EUR 2.5 million claim on terms that are not punitive to the 24% minority, and preserving the EUR 6.4 million of tax losses through the change of control. Each of these is uncertain, and the first has already failed once.

Downside is bounded in euro terms by the tiny market capitalisation, but it is real in percentage terms. Liquidation, or a highly dilutive recapitalisation at today's depressed price, would leave little for minorities. Trading is so thin that even entering or exiting a small position is impractical.

Verdict: Cumulex is uninvestable on fundamentals and is a speculative special-situation option only for investors comfortable with sponsor dependence and related-party risk. The key monitorable is the content and pricing of any Value8 debt-conversion or asset-injection proposal, together with the renewal of Value8's letter of support beyond June 2027.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenurePrior / other rolesAgeCompensation FY2025Source

Drs. Peter Paul F. de Vries

Chairman

Reappointed 16 Feb 2021 for up to 6 years; reappointed again 8 Jun 2026. Mandate start in current form 2021; earlier start date not publicly disclosed

Board member / CEO of Value8 NV (controlling shareholder)

Born 1967 (≈59)

EUR 0 (unpaid mandate)

AR FY2025; Beursgenoten/ShareCompany; VEB 2021

Drs. Gerben P. Hettinga

Managing director (gedelegeerd bestuurder)

As above

Board member of Value8 NV. Value8 AR 2021 lists a non-executive role at IEX Group NV

Born 1977 (≈49)

EUR 0

AR FY2025; Value8 AR 2021; Beursgenoten

Agnieszka Boekhout-Topolski

Director (new)

Appointed 8 Jun 2026

Banking experience incl. ING Group; currently a customer expert at listed IFF

—

Not publicly disclosed (mandates historically unpaid)

Press release 9 Jun 2026

Noëlle van der Krogt

Director (new)

Appointed 8 Jun 2026

Business economist; Business Controller at Bitvavo; focus on finance and compliance

——

Press release 9 Jun 2026

Frank Lagerveld (†)

Director (new)

Appointed 8 Jun 2026; died 26 Jun 2026

Founder and director of Doornbos Lagerveld & Partners (Luxembourg); board and supervisory experience at listed companies

——

Press releases 9 Jun 2026 and 31 Jul 2026

“—” = not publicly disclosed.

Governance Overview

MetricPre-8 Jun 2026Post-26 Jun 2026

Board size

24

Value8-affiliated directors

22

Directors not affiliated with Value8

02

Women on board

02

Chair / CEO separation

No CEO exists; the chair is a Value8 director

Unchanged

Board & Management Changes

DateChangeContext

11 May 2026

Board expansion announced ahead of AGM

Press release

8 Jun 2026

Three new directors appointed; de Vries and Hettinga reappointed

Response to governance gaps flagged by the auditor

26 Jun 2026

F. Lagerveld deceased

Board reverts to 4 members

Major Shareholders

HolderVotes% of votesTypeSource

Value8 NV (Bussum, NL)

416,65075.75

Shares / profit certificates

AR FY2025; transparency register

Jacobus Pieter Visser (Nieuwkoop, NL)

40,0007.27

Shares / profit certificates

AR FY2025

Free float / undisclosed holders

93,35016.98—

Analyst calc. (550,000 − 456,650)

Competitive Landscape

Competitor Detail

Alternative route to a listingExample (named only where verified)Positioning vs Cumulex

Sister shell controlled by the same sponsor

MKB Nedsense NV (Euronext Amsterdam), in which Value8 holds a majority stake

Same sponsor (Value8); competes for the same pipeline of injectable assets

Traditional IPO on Euronext Brussels / Growth / Access

Not company-specific

More expensive and slower, but no legacy liabilities; Cumulex offers speed and an existing listing

SPAC / blank-cheque vehicles

Not company-specific

Usually come with trust cash; Cumulex has none and carries EUR 2.5m of related-party debt

Other dormant Euronext shells

—

Comparable revenue, margins and R&D data are not publicly disclosed for a benchmark set

Competitor Detail — Revenue

Metric (FY2025)Cumulex NV

Revenue (EUR)

0

R&D intensity

0

Recent Developments

Every identifiable dated event is listed, including relevant parent-company (Value8) events, which are flagged.

Categories with no events: contract wins, product launches, guidance revisions, litigation, regulatory sanctions, layoffs and hiring.

Company Snapshot

1956

Founded

Diegem, Belgium

Headquarters

SWOT Analysis

Strengths

  • Live regulated-market listing on Euronext Brussels: ISIN BE0003463685 quoted; ESEF-compliant AR FY2025 confirmed by BDO
  • Committed sponsor with an irrevocable continuity guarantee: Value8 letter of support to the AGM of 14 Jun 2027 (AR FY2025)
  • Very low and predictable cash burn: Operating costs of EUR 70.6k (FY2024) and 74.8k (FY2025)
  • Large tax-loss pool: EUR 6,444,660 carry-forward losses, usable without time limit in principle (AR FY2025 note 6.13)
  • Funding is interest-free: The Value8 claim is explicitly non-interest-bearing (AR FY2025 note 6.15)
  • Clean audit opinion: Unqualified BDO opinion on FY2025 (17 Apr 2026)
  • Board strengthened: Two non-Value8 directors with finance and compliance backgrounds appointed 8 Jun 2026

Weaknesses

  • No operations, revenue or employees: Revenue nil FY2021–FY2025
  • Deeply negative equity: −EUR 2,540,376 at FY2025, versus capital of EUR 1,835,000
  • Essentially no assets: Total assets EUR 104; cash EUR 102 (FY2025)
  • Total dependence on one creditor and shareholder: Value8 claim EUR 2,516,206 = 99% of liabilities
  • Governance deficits: BDO flagged breaches of CCA Arts. 7:85, 7:86 and 7:99 §3, and late filing of FY2024 accounts
  • Extreme illiquidity: Prior-session volume of 4 shares (Beursgenoten, 30 Sep 2026); free float about 17% of votes
  • Failed flagship transaction: AA Circular not closed three years after shareholder approval (AR FY2025)

Opportunities

  • Reverse listing of a profitable private company: Stated strategy (website; AR FY2025)
  • Revival of the AA Circular deal: Board says it is "not excluded" (AR FY2025); target had revenue above EUR 7m and an EBITDA margin of about 15% in 2021
  • Balance-sheet repair via debt-to-equity conversion: Board signals possible conversion of the EUR 2.52m claim plus EUR 1.21m conditional waiver; authorised capital EUR 1.835m (AR FY2025)
  • Monetising tax losses: EUR 6.44m pool. At a 25% Belgian corporate tax rate, the illustrative gross shield is about EUR 1.6m, subject to change-of-control limits (analyst calc.)
  • Pipeline from Value8's portfolio: Value8 runs multiple listed and unlisted holdings (Value8 website; VEB 2025)
  • Improved governance aiding credibility with targets: Board now 50% female, with 2 non-Value8 members (Jun 2026)

Threats

  • Minority dilution in any recapitalisation: Illustrative AA Circular conversion would have taken Value8 to about 91% (analyst calc. from AR FY2023 terms)
  • Loss of tax losses on change of control: WIB 1992 "legitimate needs" test (AR FY2025)
  • Sponsor capacity and priority risk: Value8's mandatory Ctac offer (Apr–Sep 2025). VEB (2025) notes Value8 has filed public-interest-entity-audited accounts only for 2022 since 2019 and relies heavily on Morefield
  • Conflict-of-interest and valuation scrutiny: VEB criticised Value8's dual role in the AA Circular plan (Dec 2021) and microcap valuations (Sep 2023)
  • Delisting or liquidation: The board itself names liquidation as a possible outcome (AR FY2025)
  • Revival of conditionally waived debt: EUR 1,205,262 revives under the "return to better fortune" clause if finances improve (AR FY2025)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
4 Apr 2025[Parent] Value8 announces a mandatory public offer for Ctac NV after crossing 30% (stake above 40%) Ctac press release 7 Apr 2025Absorbs Value8's capital and management attention; Value8 is Cumulex's sole funder
8 Apr 2025FY2024 results: loss EUR −71k; equity −EUR 2.5m; audited accounts published Cumulex press releaseRoutine
10 Jun 2025AGM (approves FY2024 accounts) FY2024 press releaseRoutine
5 Sep 2025[Parent] Value8 publishes the Ctac offer memorandum MarketScreener/PUBTParent capital allocation
15 Sep 2025[Parent] Value8 discloses a stake in Knaus Tabbert De Aandeelhouder headline listParent portfolio activity
17 Sep 2025[Parent] Value8 says it is not targeting a majority in Ctac De Aandeelhouder headline listParent strategy
30 Sep 2025H1 2025: result −EUR 41k; EPS −0.07; equity −EUR 2.5m; costs relate only to administration, accounts, AGM and listing Cumulex press releaseConfirms no operating income
2 Oct 2025[Parent] Value8 reaches 5% of Knaus Tabbert De Aandeelhouder headline listParent portfolio
3 Apr 2026Board signs the FY2025 annual report; the Value8 letter of support is extended to the 2027 AGM AR FY2025Going-concern support renewed
17 Apr 2026BDO issues an unqualified opinion, with emphases of matter on Value8 support and the Kiliba write-down, plus legal non-compliance notes AR FY2025 auditor's reportGovernance red flags formally recorded
22 Apr 2026FY2025 results: loss EUR −75k; EPS −0.14; equity −EUR 2.5m Cumulex press releaseRoutine
11 May 2026AGM convened for 8 Jun 2026; agenda includes reappointing 2 directors and appointing 3 new ones Cumulex press releaseGovernance remediation
8 Jun 2026AGM unanimously appoints Lagerveld, Boekhout-Topolski and van der Krogt; board of 5 Press release 9 Jun 2026First non-Value8 and female directors
26 Jun 2026Director Frank Lagerveld dies Press release 31 Jul 2026Board reduced to 4
21 Jul 2026Recorded close of EUR 0.66 (StockAnalysis); 52-week range EUR 0.66–0.755Price weakness / illiquidity
31 Jul 2026H1 2026: operating result −EUR 42k; EPS −7.7c; strategy reiterated Cumulex press release; De Aandeelhouder (Belgium)Status quo
30 Sep 2026Last recorded trade at EUR 0.66 (prior-session volume 4 shares) BeursgenotenExtreme illiquidity

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment (EUR): Segment operating result rose from EUR -75,906 in FY2023 to EUR -74,797 in FY2025.
Cumulex N.V. — Revenue by Segment (EUR)
Series (EUR)FY2023FY2024FY2025
Segment operating result-75,906-70,558-74,797
Segment pre-tax result-75,906-70,558-74,797

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Cumulex NV — homepage and "Over Cumulex": and: cumulex.be · cumulex.be
  2. Cumulex NV — Annual Report FY2025 (incl. BDO auditor's report, 17 Apr 2026) (cumulex.be)
  3. Cumulex NV — Annual Report FY2023 (cumulex.be)
  4. Cumulex NV — Annual Report FY2022 (cumulex.be)
  5. Cumulex NV — Financial publications index (cumulex.be)
  6. Cumulex NV — Press releases 2020–2026: (pages 1–3) (cumulex.be)
  7. Cumulex NV — Special board report on the convertible bond (2022) (cumulex.be)
  8. StockAnalysis — Cumulex N.V. (EBR:CLEX) (stockanalysis.com)
  9. Beursgenoten — Cumulex quote and profile (ShareCompany/BIQH data): and /profiel (beursgenoten.nl)
  10. ProRealTime — Euronext Brussels instrument list (prorealtime.com)
  11. FinancialFilings — Euronext Brussels listings (financialfilings.com)
  12. VEB — Value8 / AA Circular / Cumulex (Dec 2021) (veb.net)
  13. VEB — Value8 microcap valuations (Sep 2023) (veb.net)
  14. VEB — Value8 decade review (2025) (veb.net)
  15. IEX.nl / ABM FN — Value8 takes majority stake in AA Circular (Dec 2021) (iex.nl)
  16. De Aandeelhouder — Cumulex coverage 2022–2026, incl. (deaandeelhouder.be)
  17. Beleggen.nl / ABM FN — Second EGM needed on Cumulex acquisition (Dec 2022) (beleggen.nl)
  18. Value8 — Listed portfolio page (value8.com)
  19. Value8 — Annual Report 2021 (value8.com)
  20. Ctac NV — Press release on Value8 mandatory bid (7 Apr 2025) (ctac.nl)
  21. MarketScreener / PUBT — Value8 Ctac offer memorandum (5 Sep 2025) (marketscreener.com)

Company filings and pages (cumulex.be)

Market-data and directory sources

Press and investor-advocacy coverage

Value8 (parent) sources

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.